Clinical Trials Logo

Microalbuminuria clinical trials

View clinical trials related to Microalbuminuria.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT02048904 Terminated - Type 2 Diabetes Clinical Trials

Use of Sitagliptin to Decrease Microalbuminuria

Start date: January 2014
Phase: Phase 4
Study type: Interventional

The people being asked to participate in this study have type 2 diabetes and abnormal levels of protein in their urine. This indicates that they are starting to develop diabetic kidney disease. The standard treatment for this is the use of one of two blood pressure medicines, either an ACE inhibitor or ARB. However, these medicines are not always completely effective in stopping/reversing the kidney disease. Some studies have previously suggested that another type of medicine, called sitagliptin, normal used to treat diabetes may also help prevent diabetic kidney disease from getting worse. This study is being performed to test the effectiveness of sitagliptin as compared to a placebo, along with a stable dose of an ACE inhibitor or ARB, to determine whether or not it will reduce protein levels in their urine. Protein levels in the urine are a marker of the severity of kidney disease.

NCT ID: NCT00961207 Terminated - Diabetes Clinical Trials

Triple Blockade of the Renin Angiotensin Aldosterone System in Diabetic (Type 1&2) Proteinuric Patients

Start date: August 2009
Phase: Phase 4
Study type: Interventional

Study Hypothesis: Reduction in albuminuria has been shown to decrease progression of diabetic nephropathy. In diabetic nephropathy patients treated with maximal antihypertensive doses with dual RAAS blockade (total daily dose valsartan 320 mg and either enalapril 40 mg or benazepril 40 mg daily, or losartan 100mg), persistent albuminuria reflects further additional RAAS activation. Microvascular renal disease due to increased RAAS activation may be more effectively treated with triple blockade by the addition of a direct renin inhibitor (DRI) Aliskiren.

NCT ID: NCT00458081 Terminated - Obesity Clinical Trials

Evaluation of the Rimonabant Impact on the Regression of Asymptomatic Damage Caused by Cardiovascular Risk Factors

RIALTO
Start date: March 2007
Phase: Phase 3
Study type: Interventional

Primary objective: - To assess the effect on microalbuminuria levels of treatment with rimonabant 20 mg versus a placebo during a 12 month period. Secondary objectives: - Percentage of patients in both arms of the study whose levels of microalbuminuria decrease, stabilise, increase towards macroalbuminuria or are unchanged after 12 months of treatment with rimonabant or placebo. - To assess the effect of treatment with rimonabant 20 mg versus placebo over a 12 month period on: - Weight and waist circumference. - Glycaemia profile: fasting glycaemia, fasting insulinaemia and HbA1c. - Lipid and lipoprotein profile: triglycerides, total cholesterol, HDL-C, LDL-C, apolipoproteins A1 and B. - Inflammatory markers - Adipocytokines. - Blood pressure. - Glomerular filtration rate. - To assess the quality of life by means of questionnaire filled in. - Safety parameters